Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB3616 plus fulvestrant versus placebo plus fulvestrant in untreated HR-positive/HER2-negative advanced breast cancer
CTR20221138Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of culmerciclib, fulvestrant in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2022; status: active.
02
Drugs
culmerciclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20221138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221138.